



# Weill Cornell Medicine

## Tunable Gene Therapy Expression System Regulated by Acyclovir

### Lead Inventor:

**Samie Jaffrey, M.D., Ph.D.**

Greenberg-Starr Professor, Pharmacology, Weill Cornell  
Medical College  
Professor of Pharmacology, Pharmacology, Weill Cornell  
Medical College

### Business Development Contact:

Jamie Brisbois  
Manager, Business Development and Licensing

(646) 962-7049  
[jamie.brisbois@cornell.edu](mailto:jamie.brisbois@cornell.edu)

# Tunable Gene Therapy Expression System Regulated by Acyclovir

## Background & Unmet Need

- Existing gene therapy systems rely on constitutive protein expression
- However, not all genetic diseases require continuous replacement of the defective gene product
- Prolonged or excessive expression of therapeutic proteins can also lead to toxicity
- Tailored therapy is essential as patients differ in required gene product levels, balancing therapeutic efficacy and toxicity
- Gene expression can be regulated by controlling the inclusion or exclusion of exons, a process known as alternative splicing
- Challenges related to off-target effects, efficiency, immunogenicity, and safety have arisen in gene expression systems employing alternative splicing
- **Unmet Need:** Simplified and safer method for regulating gene expression

## Technology Overview

- **The Technology:** A system that utilizes acyclovir to regulate gene expression via alternative splicing of a poison exon
- A novel splicing cassette which incorporates exon 7 of survival motor neuron 1 (SMN1) as a poison exon
- The poison exon contains an in-frame stop codon, and a TSL2 stem loop modified with an acyclovir binding aptamer that can control inclusion of the exon
- In the presence of acyclovir, the poison exon is removed from mature mRNA allowing functional protein expression
- Acyclovir is an FDA-approved antiviral that is known to be well tolerated during chronic dosage
- **PoC Data:** Insertion of the splicing cassette into a luciferase reporter gene led to significant repression of reporter expression, with dose-dependent induction up to 300-fold upon acyclovir addition

## Inventors:

Samie Jaffrey  
Qian Hou

## Patents:

Provisional Filed

## Publications:

N/A

## Biz Dev Contact:

Jamie Brisbois  
(646) 962-7049  
[jamie.brisbois@cornell.edu](mailto:jamie.brisbois@cornell.edu)

## Cornell Reference:

D-10850



# Tunable Gene Therapy Expression System Regulated by Acyclovir


## Technology Applications

- Incorporated into current gene therapy systems for better-controlled gene expression in terms of both levels and timing
- Adaptable tool for cellular biology research, where controlling protein expression is essential

## Technology Advantages

- Utilizes FDA-approved acyclovir for regulation, offering a safer and more specific approach
- Avoids the addition of exogenous amino acids, reducing the risk of protein misfolding and immune responses

## Supporting Data / Figures



**Figure 1:** Schematic showing how splicing cassette regulates gene expression (**top**). Acyclovir-induced activation of the luciferase reporter gene correlated with dosage (**bottom**).

## Inventors:

Samie Jaffrey  
Qian Hou

## Patents:

Provisional Filed

## Publications:

N/A

## Biz Dev Contact:

Jamie Brisbois  
(646) 962-7049  
[jamie.brisbois@cornell.edu](mailto:jamie.brisbois@cornell.edu)

## Cornell Reference:

D-10850



# Weill Cornell Medicine